Onesource Specialty Pharma Limited — Board Meeting, 05-05-2025: Outcome of Board Meeting

OneSource Specialty Pharma has announced a board meeting to approve the financial results for the quarter and half-year. The consolidated numbers show a quarterly profit of Rs. 991.92 million, a strong turnaround from previous losses, despite a full-year loss of Rs. 172.81 million. Following its merger with Strides Pharma Science and Steriscience, the company recognized goodwill of Rs. 3,827.53 Cr, highlighting expanded scale and capabilities. It fully redeemed listed NCDs and raised Rs. 7952.39 million via fresh equity, supported by Rs. 802.84 million from partly paid shares. New Manufacturing Services Agreements underpin optimism for CDMO growth. M/s DV & Associates are appointed Secretarial Auditor for five years, and Singapore subsidiaries will be consolidated to improve efficiency.